Compare ADMA Biologics Inc (ADMA) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs YieldMax AMD Option Income Strategy ETF — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while YieldMax AMD Option Income Strategy ETF trades at $52.89. The key difference: YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AMDY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $59.52 |
52-Week Low | $7.60 | $29.80 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AMDY trades at $56.10, up 5.35% in the last 24 hours, with technical indicators showing a bullish trend. The stock exhibits strong weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights high-yield potential alongside concerns over net asset value erosion due to its option income strategy.
The outlook for AMDY is mixed; high dividend yields attract income investors, but structural risks from NAV erosion and dependency on AMD's stock performance pose significant challenges. Investors should weigh the income benefits against potential capital depreciation in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →
